Bracketing approach for multiple strenght product EMA [Regulatives / Guidelines]

posted by jag009  – NJ, 2021-07-06 21:19 (1021 d 20:15 ago) – Posting: # 22462
Views: 1,328

Hi all,

For drug product which have multiple strengths (lets say 3), my thinking is to run a BE study comparing highest and lowest strength, and present dissolution similarities between the three strengths + a formulation composition table showing that the formulations are proportional.

Question: What if the product release > 85% within 15 mins? If so then one can't use dissolution to demonstrate similarity.

The product is BCS class 2.

Thx

J

Complete thread:

UA Flag
Activity
 Admin contact
22,991 posts in 4,827 threads, 1,648 registered users;
70 visitors (1 registered, 69 guests [including 5 identified bots]).
Forum time: 17:34 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5